William Cole Arnold

William Cole Arnold

Auto-generated profile, based on publicly available information

William Cole Arnold

University of Texas Health San Antonio 1 Department of Obstetrics and Gynecology San Antonio, Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the United States, with a median survival period of approximately 10 months. There is an urgent need for the development of effective targeted therapies for the treatment of HCC. Proline-, glutamic acid–, and leucine-rich protein 1 (PELP1) signaling is implicated in the progression of many cancers, although its specific contribution to the progression of HCC is not yet well understood. Analysis of The Cancer Genome Atlas HCC gene expression data sets and IHC analysis of HCC tissue microarray revealed that HCC tumors had elevated expression of PELP1 compared with normal tissues, and high expression of PELP1 is associated with unfavorable survival outcomes. Suppression of PELP1 expression using short hairpin RNA significantly reduced the cell viability, clonogenicity, and invasion of HCC cells. Importantly, SMIP34, a first-in-class small-molecule inhibitor targeting PELP1, effectively decreased the cell viability, clonogenic survival, and invasiveness of HCC cells. Gene expression analysis using RNA sequencing revealed that PELP1 knockdown cells exhibited a decrease in c-Myc, E2F, and other oncogenic pathways related to HCC. Mechanistic studies showed that SMIP34 treatment impaired the Rix complex, a critical component of ribosomal biogenesis, in HCC cells. Furthermore, the knockdown or pharmacologic inhibition of PELP1 significantly decelerated the HCC tumor growth in xenograft models. In summary, our study findings indicate that PELP1 could serve as a promising target for therapeutic intervention in HCC. Significance: HCC is one of the leading causes of cancer fatalities in the United States. Effective targeted therapeutics for HCC are urgently needed. In this study, we show that PELP1 proto-oncogene is crucial to HCC progression and that PELP1 inhibition reduced HCC cell proliferation in vitro and in vivo. Our results imply that PELP1-targeted drugs like SMIP34 may be useful as new therapeutic agents for HCC treatment.

7 October 2024
Verified
Other
Open access
PDF file
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
Figure S1. Levels of PELP1 expression in 6 HCC cell lines.

7 October 2024
Verified
Other
Open access
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
PELP1 expression is upregulated in HCC, and high PELP1 expression is associated with poor survival of patients with HCC. Data obtained from TNMplot shows increased expression of PELP1 in patients with HCC (A). The results from TCGA-UALCAN database show that PELP1 expression is increased with HCC progression (B). The Clinical Proteomic Tumor Analysis Consortium database shows high PELP1 expression in HCC tumor tissues compared with normal tissues (C). Association of protein expression of PELP1 with overall survival of patients with HCC was obtained from The Human Protein Atlas (D). TMA was used to investigate the PELP1 expression in 86 HCC and six normal liver specimens by IHC and quantified (E and F). Scale bar, 100 μm. P values are calculated using the Student t test. ****, p < 0.0001.

7 October 2024
Verified
Other
Open access
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
PELP1-KD or SMIP34 treatment suppresses HCC xenograft tumor growth in vivo. Hep3B–control and Hep3B–PELP1-KD model cells were injected subcutaneously into female (A, D, and G) or male SCID mice (B, E, and H). Tumor volumes were assessed at 3 to 5 days of intervals. Tumor volume (A and B), tumor weights (D and E), and IHC analyses of Ki67 and PELP1 (G and H) for tumors are shown. Hep3B xenograft tumor fragments measuring 2 to 3 mm3 were implanted subcutaneously , and following tumor establishment (∼200 mm3), the mice were randomly assigned to receive either vehicle (control) or SMIP34 (20 mg/kg body weight) 5 days a week through i.p. injection (n = 5). Tumor volume (C), tumor weights (F) and IHC analyses of Ki67 and PELP1 (I) for tumors are shown. Scale bar, 100 μm. Data are represented as the mean ± SEM. P values are calculated using Student t test and two-way ANOVA, *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Cont sh (Control short hairpin).

7 October 2024
Verified
Other
Open access
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the United States, with a median survival period of approximately 10 months. There is an urgent need for the development of effective targeted therapies for the treatment of HCC. Proline-, glutamic acid–, and leucine-rich protein 1 (PELP1) signaling is implicated in the progression of many cancers, although its specific contribution to the progression of HCC is not yet well understood. Analysis of The Cancer Genome Atlas HCC gene expression data sets and IHC analysis of HCC tissue microarray revealed that HCC tumors had elevated expression of PELP1 compared with normal tissues, and high expression of PELP1 is associated with unfavorable survival outcomes. Suppression of PELP1 expression using short hairpin RNA significantly reduced the cell viability, clonogenicity, and invasion of HCC cells. Importantly, SMIP34, a first-in-class small-molecule inhibitor targeting PELP1, effectively decreased the cell viability, clonogenic survival, and invasiveness of HCC cells. Gene expression analysis using RNA sequencing revealed that PELP1 knockdown cells exhibited a decrease in c-Myc, E2F, and other oncogenic pathways related to HCC. Mechanistic studies showed that SMIP34 treatment impaired the Rix complex, a critical component of ribosomal biogenesis, in HCC cells. Furthermore, the knockdown or pharmacologic inhibition of PELP1 significantly decelerated the HCC tumor growth in xenograft models. In summary, our study findings indicate that PELP1 could serve as a promising target for therapeutic intervention in HCC.Significance:HCC is one of the leading causes of cancer fatalities in the United States. Effective targeted therapeutics for HCC are urgently needed. In this study, we show that PELP1 proto-oncogene is crucial to HCC progression and that PELP1 inhibition reduced HCC cell proliferation in vitro and in vivo. Our results imply that PELP1-targeted drugs like SMIP34 may be useful as new therapeutic agents for HCC treatment.

7 October 2024
Verified
Other
Open access
PDF file
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
XYXue Yang
Xue Yang
ABAdriana Baker
Adriana Baker
RGRahul Gopalam
Rahul Gopalam
WAWilliam C. Arnold
William C. Arnold
UPUday Pratap
Uday Pratap
Figure S2. SMIP34 treatment downregulates liver specific genes, MYC and E2F pathway targeted genes in HCC cells.